SEC Form 4 · accession 0001645627-17-000015
ENDONOVO THERAPEUTICS, INC. · ENDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Scott Mann
Officer — President · 10% Owner
Period of report
Feb 14, 2017
Accepted (ET)
Mar 2, 2017 · 8:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 14, 2017 | P | 500 | $0.0119 | A | 19,758,849 | D | |
| Common Stock | Feb 14, 2017 | P | 500 | $0.013 | A | 19,759,349 | D | |
| Common Stock | Feb 14, 2017 | P | 500 | $0.013 | A | 19,759,849 | D | |
| Common Stock | Feb 14, 2017 | P | 1,000 | $0.0134 | A | 19,760,849 | D | |
| Common Stock | Feb 14, 2017 | P | 500 | $0.013 | A | 19,761,349 | D | |
| Common Stock | Feb 14, 2017 | P | 500 | $0.013 | A | 19,761,849 | D | |
| Common Stock | Feb 15, 2017 | P | 500 | $0.0107 | A | 19,762,349 | D | |
| Common Stock | Feb 15, 2017 | P | 500 | $0.0108 | A | 19,762,849 | D | |
| Common Stock | Feb 15, 2017 | P | 1,000 | $0.011 | A | 19,763,849 | D | |
| Common Stock | Feb 15, 2017 | P | 1,000 | $0.011 | A | 19,764,849 | D | |
| Common Stock | Feb 15, 2017 | P | 1,000 | $0.0118 | A | 19,765,849 | D | |
| Common Stock | Feb 15, 2017 | P | 1,000 | $0.0118 | A | 19,766,849 | D | |
| Common Stock | Feb 15, 2017 | P | 500 | $0.0118 | A | 19,767,349 | D | |
| Common Stock | Feb 15, 2017 | P | 200 | $0.0113 | A | 19,767,549 | D | |
| Common Stock | Feb 15, 2017 | P | 1,000 | $0.0114 | A | 19,768,549 | D | |
| Common Stock | Feb 15, 2017 | P | 1,000 | $0.0109 | A | 19,769,549 | D | |
| Common Stock | Feb 16, 2017 | P | 1,000 | $0.0135 | A | 19,770,549 | D | |
| Common Stock | Feb 17, 2017 | P | 100 | $0.0177 | A | 19,770,649 | D | |
| Common Stock | Feb 21, 2017 | P | 1,000 | $0.0178 | A | 19,771,649 | D | |
| c | Feb 22, 2017 | P | 1,000 | $0.016 | A | 19,772,649 | D |
Table II — derivative securities
No Table II lines on this filing.